Search Results - "Margery, Jacques"

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial by Zalcman, Gérard, Prof, Mazieres, Julien, Prof, Margery, Jacques, MD, Greillier, Laurent, MD, Audigier-Valette, Clarisse, MD, Moro-Sibilot, Denis, Prof, Molinier, Olivier, MD, Corre, Romain, MD, Monnet, Isabelle, MD, Gounant, Valérie, MD, Rivière, Frédéric, MD, Janicot, Henri, MD, Gervais, Radj, MD, Locher, Chrystèle, MD, Milleron, Bernard, MD, Tran, Quan, MSc, Lebitasy, Marie-Paule, MD, Morin, Franck, MSc, Creveuil, Christian, PhD, Parienti, Jean-Jacques, Prof, Scherpereel, Arnaud, Prof

“…Summary Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure. Vascular endothelial…”
Get full text

Lung cancer and end-of-life care: a systematic review and thematic synthesis of aggressive inpatient care by Bylicki, Olivier, Didier, Morgane, Riviere, Frederic, Margery, Jacques, Grassin, Frederic, Chouaid, Christos

“…Despite recent advances in thoracic oncology, most patients with metastatic lung cancer die within months of diagnosis. Aggressiveness of their end-of-life…”
Get more information

Noninvasive Diagnosis of Actionable Mutations by Deep Sequencing of Circulating Free DNA in Lung Cancer from Never-Smokers: A Proof-of-Concept Study from BioCAST/ IFCT-1002 by COURAUD, Sébastien, VACA-PANIAGUA, Felipe, PRIM, Nathalie, VINCENT, Michel, MARGERY, Jacques, LARIVE, Sébastien, FOUCHER, Pascal, DUVERT, Bernard, VALLEE, Maxime, LE CALVEZ-KELM, Florence, McKAY, James, MISSY, Pascale, VILLAR, Stéphanie, MORIN, Franck, ZALCMAN, Gérard, OLIVIER, Magali, SOUQUET, Pierre-Jean, OLIVER, Javier, SCHUSTER, Tibor, BLANCHE, Hélène, GIRARD, Nicolas, TREDANIEL, Jean, GUILLEMINAULT, Laurent, GERVAIS, Radj

“…Tumor somatic mutation analysis is part of the standard management of metastatic lung cancer. However, physicians often have to deal with small biopsies and…”
Get full text

Medical follow-up of workers exposed to lung carcinogens: French evidence-based and pragmatic recommendations by Delva, Fleur, Margery, Jacques, Laurent, François, Petitprez, Karine, Pairon, Jean-Claude

“…The aim of this work was to establish recommendations for the medical follow-up of workers currently or previously exposed to lung carcinogens. A critical…”
Get full text

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer by Bylicki, Olivier, Paleiron, Nicolas, Margery, Jacques, Guisier, Florian, Vergnenegre, Alain, Robinet, Gilles, Auliac, Jean-Bernard, Gervais, Radj, Chouaid, Christos

“…Immune checkpoint inhibitors, notably antibodies targeting programmed death–1 (PD-1) and programmed death ligand–1 (PD-L1), have modified the management of…”
Get full text

A defect of amphiregulin release predicted longer survival independently of YAP expression in patients with pleural mesothelioma in the IFCT‐0701 MAPS phase 3 trial by Maille, Elodie, Levallet, Jérôme, Dubois, Fatéméh, Antoine, Martine, Danel, Claire, Creveuil, Christian, Mazieres, Julien, Margery, Jacques, Greillier, Laurent, Gounant, Valérie, Moro‐Sibilot, Denis, Molinier, Olivier, Léna, Hervé, Monnet, Isabelle, Bergot, Emmanuel, Langlais, Alexandra, Morin, Franck, Scherpereel, Arnaud, Zalcman, Gérard, Levallet, Guénaëlle

“…The Hippo pathway effector YAP is dysregulated in malignant pleural mesothelioma (MPM). YAP's target genes include the secreted growth factor amphiregulin…”
Get full text

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial by Maille, Elodie, Brosseau, Solenn, Hanoux, Vincent, Creveuil, Christian, Danel, Claire, Bergot, Emmanuel, Scherpereel, Arnaud, Mazières, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Gounant, Valérie, Langlais, Alexandra, Morin, Franck, Levallet, Guénaëlle, Zalcman, Gérard

“…Background The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS/NCT00651456) phase 3 trial demonstrated the superiority of bevacizumab plus…”
Get full text

LUCSO-1—French pilot study of LUng Cancer Screening with low-dose computed tomography in a smokers population exposed to Occupational lung carcinogens: study protocol by Delva, Fleur, Laurent, François, Paris, Christophe, Belacel, Milia, Brochard, Patrick, Bylicki, Olivier, Chouaïd, Christos, Clin, Benedicte, Dewitte, Jean-Dominique, Le Denmat, Véronique, Gehanno, Jean-François, Lacourt, Aude, Margery, Jacques, Verdun-Esquer, Catherine, Mathoulin-Pélissier, Simone, Pairon, Jean-Claude

“…IntroductionGuidelines concerning the follow-up of subjects occupationally exposed to lung carcinogens, published in France in 2015, recommended the setting up…”
Get full text

Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting by Bylicki, Olivier, Rouvière, Damien, Cassier, Philippe, Chalabreysse, Lara, Levard, Alice, Maury, Jean-Michel, Margery, Jacques, Blay, Jean-Yves, Mazières, Julien, Girard, Nicolas

“…Solitary fibrous tumors of the pleura (SFTP) refer as to a heterogeneous group of mesenchymal malignancies with various anatomic and histology features…”
Get more information

Isolation of Nocardia beijingensis from a Pulmonary Abscess Reveals Human Immunodeficiency Virus Infection by MARTINAUD, Christophe, VERDONK, Charles, BOUSQUET, Aurore, MACNAB, Christine, VAYLET, Fabien, SOLER, Charles, SAMSON, Thierry, MARGERY, Jacques

“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Phase II Study of Vinflunine in Malignant Pleural Mesothelioma by TALBOT, Denis C, MARGERY, Jacques, RUFFLE, Pierre, DABOUIS, Gérard, DARK, Graham, TAYLOR, Henry, BOUSSEMART, Hélène, CADIC, Véronique, PINEL, Marie-Claire, RIVIERE, Alain, OLLIVIER, Liliane

“…Malignant pleural mesothelioma (MPM) is a disease of increasing incidence for which treatment options are limited. This study reports the clinical efficacy…”
Get full text

Adult Ascaris Worm Passing from the Mouth by MARGERY, Jacques, NIANG, Abdourahmane

Get full text

First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors by Bylicki, Olivier, Barazzutti, Helene, Paleiron, Nicolas, Margery, Jacques, Assié, Jean-Baptiste, Chouaïd, Christos

“…Treatment of advanced-stage or metastatic non-small-cell lung cancers (NSCLCs) without EGFR mutations or ALK rearrangements, which can now be treated with…”
Get full text

Bronchoscopy with the Vision Sciences BF100 disposable-sheath device: French experience after 328 procedures by Margery, Jacques, Vaylet, Fabien, Guigay, Joël, Grassin, Frédéric, Dot, Jean-Marc, Morel, Vincent, Vaures, Evelyne, Marotel, Claude, Demuys, Christelle, L'Her, Pierre

“…In spite of adhesion to recommended disinfection procedures, the transmission of infections by bronchoscopes is a permanent problem. The new device may prevent…”
Get more information

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort by Brosseau, Solenn, Danel, Claire, Scherpereel, Arnaud, Mazières, Julien, Lantuejoul, Sylvie, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Gounant, Valérie, Antoine, Martine, Moro-Sibilot, Denis, Rouquette, Isabelle, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Langlais, Alexandra, Morin, Franck, Bergot, Emmanuel, Zalcman, Gérard, Levallet, Guénaëlle

“…Anticancer immune responses are negatively regulated by programmed cell death 1 (PD-1) T-cell membrane protein interaction with its ligand, programmed death…”
Get full text

SS68-03 OCCUPATIONAL HEALTH SURVEILLANCE FOR WORKERS EXPOSED TO LUNG CARCINOGENS by Delva, Fleur, Pairon, Jean-Claude, Margery, Jacques, Laurent, François, Petitprez, Karine, André, Michel, Bessette, Dominique, Brochard, Patrick, Certin, Jean-François, Chouaid, Christos, Clin-Godard, Bénédicte, Goutet, Pierre, Grenier, Philippe, Ibanez, Gladys, Iwatsubo, Yuriko, Lebaupain, Claudie, Leroy, Chloé, Milleron, Bernard, Paris, Christophe, Stücker, Isabelle, Thouveny, Gilbert, Tirmarche, Dominique, Vandame, Martine, Vandenberghe, Odile

Get full text

Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial by Eberst, Guillaume, Anota, Amélie, Scherpereel, Arnaud, Mazieres, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Léna, Hervé, Rivière, Frédéric, Monnet, Isabelle, Gounant, Valérie, Janicot, Henri, Gervais, Radj, Locher, Chrystelle, Charton, Emilie, Morin, Franck, Zalcman, Gérard, Westeel, Virginie

“…The IFCT-GFPC-0701 MAPS phase III trial highlighted significant improvement in overall survival from adding bevacizumab to the standard first-line chemotherapy…”
Get full text

Switch maintenance chemotherapy versus observation after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non–small cell lung cancer: IFCT-1201 MODEL trial by Quoix, Elisabeth, Audigier-Valette, Clarisse, Lavolé, Armelle, Molinier, Olivier, Westeel, Virginie, Barlesi, Fabrice, Le Treut, Jacques, Pichon, Eric, Dauba, Jérôme, Otto, Josiane, Moreau, Lionel, Madelaine, Jeannick, Dumont, Patrick, Margery, Jacques, Debieuvre, Didier, Renault, Patrick Aldo, Pujol, Jean-Louis, Langlais, Alexandra, Morin, Franck, Moro-Sibilot, Denis, Souquet, Pierre-Jean

“…Maintenance chemotherapy is a reasonable choice for patients with metastatic non–small cell lung carcinoma (NSCLC) not progressing after induction therapy with…”
Get full text

Factors Associated With Aggressiveness of End-of-Life Care for Lung Cancer Patients and Associated Costs of Care by Bylicki, Olivier, Rivière, Fréderic, Tournier, Charlène, Canoui-Poitrine, Florence, Grassin, Fréderic, Margery, Jacques, Prodel, Martin, Vainchtock, Alexandre, Assié, Jean-Baptiste, Chouaïd, Christos

“…Results of previous studies demonstrated that high-intensity end-of-life (EOL) care improves neither cancer patients’ survival nor quality of life. Our…”
Get full text

Tailoring maintenance chemotherapy upon response to induction chemotherapy as compared with pemetrexed continuation maintenance in advanced non-squamous NSCLC patients: Results of the IFCT-GFPC-1101 multicenter randomized phase III trial by Souquet, Pierre-Jean, Audigier-Valette, Clarisse, Molinier, Olivier, Cortot, Alexis, Margery, Jacques, Moreau, Lionel, Gervais, Radj, Barlesi, Fabrice, Pichon, Eric, Zalcman, Gérard, Dumont, Patrick, Girard, Nicolas, Poudenx, Michel, Mazières, Julien, Cadranel, Jacques, Debieuvre, Didier, Dauba, Jérôme, Langlais, Alexandra, Morin, Franck, Moro-Sibilot, Denis, Westeel, Virginie, Pérol, Maurice

“…•Adapting maintenance according to response to chemo (SD/OR) doesn’t improve survival.•Doublet with G or P, have equivalent efficacy in contrast to the JMDB…”
Get full text